

Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features

Mimica, Ninoslav; Mück-Šeler, Dorotea; Pivac, Nela; Mustapić, Maja; Deželjin, Martina; Stipčević, Tamara; Presečki, Paola; Radonić, Elizabeta; Folnegović-Šmalc, Vera

Source / Izvornik: **Collegium Antropologicum, 2008, 32, 119 - 122**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:688163>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-03-13**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



Platelet Serotonin and Monoamine Oxidase in Alzheimer's Disease with Psychotic Features

Ninoslav Mimica^{1,2}, Dorotea Mück-Šeler³, Nela Pivac³, Maja Mustapić³, Martina Deželjin³, Tamara Stipčević³, Paola Presečki⁴, Elizabeta Radonić⁵ and Vera Folnegović-Šmalc^{1,2}

¹ Department of Psychiatry, Psychiatric Hospital »Vrapče«, Zagreb, Croatia

² School of Medicine, University of Zagreb, Zagreb, Croatia

³ Division of Molecular Medicine, »Ruđer Bošković« Institute, Zagreb, Croatia

⁴ Department of Psychiatry, General Hospital »Pula«, Pula, Croatia

⁵ Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia

ABSTRACT

Post mortem brain studies indicate that alterations in serotonergic and catecholaminergic systems might be associated with Alzheimer's disease (AD). The aim of the study was to determine serotonin (5-HT) levels and monoamine oxidase type B (MAO-B) activity in platelets of psychotic and non-psychotic patients with AD, established according to the NINCDS-ADRDA and DSM-IV-TR criteria. Cognitive impairment and psychotic features were evaluated using Mini Mental Status Examination and Neuropsychiatric Inventory. Platelet 5-HT concentration and MAO-B activity were determined spectrofluorimetrically in 116 (51 male, 65 female) healthy subjects and 70 psychotic (10 male, 60 female) and 151 non-psychotic (32 male, 119 female) patients. Psychotic and non-psychotic female and psychotic male patients had significantly lower platelet 5-HT concentration than corresponding sex matched control subjects. Platelet MAO-B activity was significantly increased in both male and female non-psychotic patients compared to the sex matched controls. Non-psychotic female patients had significantly higher platelet MAO-B activity than psychotic female patients. Our data suggest that platelet MAO-B activity, but not platelet 5-HT concentration, could differentiate between psychotic and non-psychotic subtypes of AD.

Key words: platelets, serotonin, monoamine oxidase, Alzheimer's disease, psychotic features

Introduction

Alzheimer's disease (AD) is a complex neurodegenerative disorder with different cognitive and behavioural abnormalities¹. Various studies have found that majority of AD patients suffer from psychotic symptoms, like auditory and/or visual hallucinations and delusions². Psychotic features upset the patients, complicate the treatment response, and are frequently associated with the rapid progress of the disease².

The aetiology of AD is still not clear. Post mortem brain studies in patients with AD³ showed neuropathological and neurochemical alterations in catecholaminergic⁴ and serotonergic⁵ systems. The decrease in brain dopamine⁶, serotonin (5-hydroxytryptamine, 5-HT)⁶, and its main metabolite 5-hydroxyindoleacetic acid (5-HIAA) concentrations, and the loss of 5-HT₂ receptors⁷, was

found in patients with AD. Blood platelets have been proposed as an easy obtainable peripheral model for some processes in the central serotonergic neurons^{8–10} and for the expression of the brain amyloid precursor protein¹¹. The studies on platelet 5-HT uptake^{12,13}, and platelet monoamine oxidase type B (MAO-B) in AD yielded inconsistent results¹⁴. MAO is a flavin-containing oxygen oxidoreductase. Two isoenzymes (MAO-A and MAO-B) differ in localization, substrates and inhibitors¹⁵. MAO-B exists in platelets, astrocytes and 5-HT neurons. Its substrates are β -phenylethylamine, benzylamine, dopamine, tyramine, and tryptamine, and its inhibitor is deprenyl¹⁵. It is assumed that altered levels of platelet MAO-B are associated with different psychopathologies and vulnerability to psychiatric disorders^{15,16}. An increase in platelet

MAO-B activity was observed in AD¹⁷. Recently we have found¹⁸ that platelet MAO-B activity might be used as a peripheral biomarker for the early and late onset AD.

We have previously found that platelet 5-HT might differentiate between psychotic and non-psychotic depression¹⁹, posttraumatic stress disorder (PTSD)²⁰, bipolar affective disorder in a manic phase²¹. In addition, a higher platelet MAO-B activity was found in psychotic compared to non-psychotic subtype of PTSD²². The hypothesis of the present study was that platelet biochemical markers would differ in AD patients with or without psychotic features. The aim of the present study was to determine peripheral biochemical markers (platelet 5-HT concentration and platelet MAO-B activity) in male and female patients with AD, subdivided according to the presence of psychotic features, and in sex matched healthy controls.

Subjects and Methods

The study included 221 (42 male, 179 female) medication-free patients (mean age 60.6±9.9 years) with AD, hospitalized in Psychiatric Hospital Vrapče, Zagreb. The diagnosis of the probable AD (NINCDS-ADRDA criteria²³) was established by two psychiatrists according to the DSM-IV-TR criteria²⁴. Cognitive impairment was evaluated using Mini Mental Status Examination (MMSE)²⁵. Mean MMSE scores in AD patients was 18.9±3.2. According to the Neuropsychiatric Inventory²⁶, patients were subdivided into two groups: 70 patients (10 male and 60 female) with psychotic features and 151 patients (32 male, 119 female) without psychotic features. Control group consisted of sex and age-matched, medication-free healthy subjects (65 female, 51 male) (mean age 60.3±11.2 years), with no history of psychiatric illness. All subjects were nonsmokers. The study was approved by the Ethic committee and all participants gave informed consent.

Blood samples (8 mL) were obtained from a jugular vein, after an overnight fasting, in a plastic syringe with 2 ml of acid citrate dextrose anticoagulant. Platelet rich plasma (PRP) was obtained after centrifugation of whole blood, and platelets were sedimented by further centrifugation of PRP. Platelet 5-HT concentration was determined by the spectrofluorimetric method, as previously described²⁷, using Varian Cary Eclipse spectrofluorimeter. Platelet MAO-B activity was determined spectrofluorimetrically using kynuramine as a substrate^{27,28}. Platelet protein levels were measured by the method of Lowry et al.²⁹.

The results were expressed as mean±SD. The differences between groups were analyzed using Kruskal-Wallis one-way analysis of variance (ANOVA) by ranks followed by Mann-Whitney rank sum test for pairwise comparisons. The statistical package used was Statistica 6 and SPSS 10.0 analysis.

Results

Platelet 5-HT concentration was significantly ($H=36.5$, $df=5$, $p<0.001$; Kruskal Wallis ANOVA) different among healthy controls and patients with AD, subdivided according to the presence of psychotic features (Figure 1). A significant decrease in platelet 5-HT concentration was observed in psychotic ($p=0.002$, Mann Whitney test) and non-psychotic ($p<0.001$) female patients and non-psychotic ($p=0.002$) male patients compared to platelet 5-HT concentration in corresponding sex-matched healthy controls. There was no significant difference in platelet 5-HT concentration between male ($p=0.712$, Mann Whitney test) or female ($p=0.422$, Mann Whitney test) psychotic or non-psychotic AD patients.




Fig. 1. Platelet serotonin (5-HT) in male and female healthy controls and patients with Alzheimer's disease (AD) with or without psychotic features. * $p=0.002$ vs. healthy male; ** $p=0.002$ vs. healthy female; # $p<0.001$ vs. healthy female (Kruskal Wallis ANOVA on ranks followed by Mann Whitney test)




Fig. 2. Platelet monoamine oxidase (MAO) in healthy controls and patients Alzheimer's disease (AD) with or without psychotic features. * $p=0.017$ vs. female psychotic patients; ** $p<0.006$ vs. healthy male; # $p<0.001$ vs healthy female (Kruskal Wallis ANOVA on ranks followed by Mann Whitney test)

Platelet MAO-B activity differed significantly ($H=28.8$, $df=5$, $p<0.001$, Kruskal Wallis ANOVA) in patients with AD, subdivided into groups with or without psychotic features, and in healthy control subjects (Figure 2). Platelet MAO-B activity was significantly higher in both male ($p<0.006$) and female ($p<0.001$) non-psychotic patients with AD than in sex matched healthy controls. Non-psychotic female AD patients had significantly ($p<0.017$) higher platelet MAO-B activity than psychotic female AD patients. There was no significant difference ($p=0.73$, Mann Whitney test) in platelet MAO activity between psychotic and non-psychotic male AD patients.

Discussion

The results of the present study show that patients with AD have different platelet 5-HT concentration and platelet MAO-B activity when compared to sex- and age-matched control subjects. To our knowledge this is the first report showing a decreased platelet 5-HT concentration in patients with AD. Although platelets represent a limited peripheral model for the central serotonergic neurons, it is noteworthy that similar reductions in 5-HT and 5-HIAA concentrations have also been found in the areas of the frontal and temporal cortices of AD patients⁵. In addition, our results showed that the alterations in platelet 5-HT values in AD patients were not related to the presence of psychotic features. This result is in contrast with the increased platelet 5-HT concentrations in psychotic unipolar depressed patients¹⁹, bipolar patients in manic phase²¹, war veterans PTSD with psychotic symptoms²⁰, or schizophrenic patients with predominantly positive symptoms³⁰, when compared to corresponding control subjects.

The discrepancies in platelet 5-HT concentration in patients with AD might be explained by the various factors, including a decrease in 5-HT synthesis, an increase in 5-HT metabolism and a change in 5-HT transporter. It has been suggested³¹ that aging may be associated with lower activity of the tryptophan hydroxylase, a rate limiting enzyme in 5-HT synthesis. Since our study included age matched patients and control subjects, the difference in platelet 5-HT values between groups is presumably not related to the difference in age of the subjects. Platelet 5-HT transporter is the most important membrane protein, responsible for the active transport of 5-HT from plasma into platelets, and consequently for platelet 5-HT concentrations. However, recent molecular study³² did not find an association between a deletion/insertion polymorphism within promoter region of the 5-HT transporter gene and AD.

Although blood platelets contain only MAO type B, which is not entirely specific for the metabolism of the 5-HT, we can not exclude the possibility that the decrease

in platelet 5-HT concentrations in patients with AD is in part a consequence of the higher platelet MAO-B activity.

In the present study we have found an increase in platelet MAO-B activity in both male and female patients with AD compared to control subjects. This is in line with our previous finding of the high platelet MAO-B activity in patients with early onset AD, and with other studies showing increased MAO activity in brain^{14,33} and platelets^{14,17,18,34} of patients with AD. In addition, we have found that the increase in platelet MAO-B activity was restricted only to patients without psychotic features. Several factors such as sex, smoking, age, race, some neurodegenerative disorders, pernicious anaemia, and psychotropic drugs¹⁵ affect platelet MAO-B activity. To control for these variables, we subdivided patients according to the sex, they were matched for race, age, and medication, and none of the patients were smokers. Higher platelet MAO-B activity reported in our non-psychotic AD patients might be connected with some hidden psychopathologies¹⁵, personality traits^{35,36}, such as neuroticism³⁷ or high anxiety³⁶. The increased platelet MAO-B activity in non-psychotic AD patients does not agree with the recent finding of an elevated activity of platelet MAO-B in war veterans PTSD with psychotic symptoms²² when compared to corresponding control subjects. This discrepancy might be due to the differences in diagnoses (AD vs. PTSD), age¹⁵ or smoking²⁰. In addition, altered platelet MAO-B activity may be related to difference in yet unknown transcriptional factor(s)³⁸, rather than genotypic variation²², that act on transcriptional regulation³⁸ of the amount of enzyme and/or in the kinetic regulation of the molecular activity of MAO-B in platelets³⁹.

Our results of the increased MAO-B activity in AD patients support the presumption that neurotoxic and reactive metabolites of catecholamine neurotransmitters could be involved in the aetiology and progress of AD. Recently, neurotoxicity of MAO-B metabolites of noradrenalin, adrenaline or dopamine has been shown in vitro and in vivo⁴⁰. The serious consequence of the altered MAO activity is the increase in catecholamine metabolites like 3, 4-dihydroxyphenylglycolaldehyde (DOPEGAL) and 3,4-dihydroxyphenylacetaldehyde (DOPAL), which are highly reactive and toxic to neuronal cells in vitro and in vivo⁴⁰.

In conclusion, we have found altered biochemical parameters in platelets of patients with AD. Our results of decreased platelet 5-HT concentrations and increased platelet MAO-B activity suggest that both serotonergic and catecholaminergic system could be involved in the pathophysiology and progress of AD. In addition, platelet MAO-B activity, but not 5-HT concentration, might be used as a peripheral biological marker that can distinguish between psychotic and non-psychotic subtypes of AD.

REFERENCES

1. THE RONALD AND NANCY REAGAN RESEARCH INSTITUTE OF THE ALZHEIMER'S ASSOCIATION AND THE NATIONAL INSTITUTE ON AGING WORKING GROUP, *Neurobiol Aging*, 19 (1998) 109.
- 2. SCHNEIDER LS, DAGERMAN KS, *J Psychiatr Res*, 38 (2004) 105.
- 3. LANARI A, AMENTA F, SILVESTRELLI G, TOMASSONI D, PARNETTI L, *Mech Ageing Dev*, 127 (2006) 158.
- 4. HERRMANN N, LANCTOT KL, KHAN LR, *J Neuropsychiatry Clin Neurosci*, 16 (2004) 261.
- 5. GARZIA-ALLOZA M, GIL-BEA FJ, DIEZ-ARIZA M, CHEN CPLH, FRANCIS PT, LASHERAS B, RAMIREZ MJ, *Neuropsychologia*, 43 (2005) 442.
- 6. STORGA D, VRECKO K, BIRKMAYER JGD, REIBNEGGER G, *Neurosci Lett*, 203 (1996) 29.
- 7. BLIN J, BARON JC, DUBOIS B, CROUZEL C, FIORELLI M, ATTAR-LEVY D, PILLON B, FOURNIER D, VIDAILHET M, AGID Y, *Brain*, 116 (1993) 497.
- 8. ANDRES AH, RAO MA, OSTROWITZKI S, ENZIAN W, *Life Sci*, 52 (1993) 313.
- 9. FRANKE L, SCHEWE HJ, MÜLLER B, CAMPMAN V, KITZROW W, UEBELHACK R, BERGHÖFER A, MÜLLER-OERLINGHAUSEN B, *Life Sci*, 47 (2000) 301.
- 10. PLAIN H, BERK M, *J Affect Disord*, 16 (2001) 229.
- 11. CATTABENI F, COLCIAGHI F, DI LUCA M, *Prog Neuropsychopharmacol Biol Psychiatry*, 28 (2004) 763.
- 12. ARORA RC, EMERY O, MELTZER HY, *Neurology*, 41 (1991) 1307.
- 13. KOREN P, DIVER-HARBER A, ADONSKY A, RABINOWITZ M, HERSHKOWITZ M, *J Gerontol*, 48 (1993) B93.
- 14. ADOLFSSON R, GOTTFRIES CG, ORELAND L, WIBERG A, WINBLAD B, *Life Sci*, 27 (1980) 1029.
- 15. ORELAND L, *Neurotoxicology*, 25 (2004) 79.
- 16. PAAVER M, EENSOO D, PULVER A, HARRO J, *Psychopharmacology*, 186 (2006) 32.
- 17. ORELAND L, GOTTFRIES CG, *Prog Neuropsychopharmacol Biol Psychiatry*, 10 (1986) 533.
- 18. MIMICA N, MUCK-SELER D, PIVAC N, MUSTAPIC M, FOLNEGOVIC-SMALC V, *Period Biol*, 106 (2004) 126.
- 19. MUCK-SELER D, JAKOVLJEVIC M, PIVAC N, *J Affect Disord*, 39 (1986) 73.
- 20. PIVAC N, KOZARIC-KOVACIC D, MUSTAPIC M, DEZELJIN M, BOROVECKI A, GRUBISIC-ILIC M, MUCK-SELER D, *J Affect Disord*, 93 (2006) 223.
- 21. SAGUD M, MIHALJEVIC-PELES A, PIVAC N, JAKOVLJEVIC M, MUCK-SELER D, *J Affect Disord*, 97 (2007), 247.
- 22. PIVAC N, KNEZEVIC J, KOZARIC-KOVACIC D, DEZELJIN M, MUSTAPIC M, RAK D, MATIJEVIC T, PAVELIC J, MUCK-SELER D, *J Affect Disord*, (2007) doi: 10.1016/j.jad.2007.01.017.
- 23. MCKHANN G, DRACHMANN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM, *Neurology*, 34 (1984) 939.
- 24. AMERICAN PSYCHIATRIC ASSOCIATION: *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision* (American Psychiatric Association, Washington, DC, 2000).
- 25. FOLSTEIN MF, FOLSTEIN SE, MCGHUGH PR, *J Psychiatr Res*, 12 (1975) 189.
- 26. CUMMINGS JL, MEGA M, GRAY K, ROSENBERG-THOMPSON S, CARUSI DA, GORNBEIN J, *Neurology*, 44 (1994) 2308.
- 27. MUCK-SELER D, PIVAC N, SAGUD M, JAKOVLJEVIC M, MIHALJEVIC-PELES A, *Prog Neuropsychopharmacol Biol Psychiatry*, 26 (2002) 1235.
- 28. KRAJL M, *Biochem Pharmacol*, 14 (1965) 1683.
- 29. LOWRY OH, ROSENBROUGH NS, FARRA C, RANDALL RJ, *J Biol Chem*, 193 (1951) 265.
- 30. PIVAC N, MUCK-SELER D, JAKOVLJEVIC M, *Neuropsychobiology*, 36 (1997) 19.
- 31. HUSSAIN AM, MITRA AK, *Drug Metab Dispos*, 28 (2000) 1038.
- 32. ZILL P, PADBERG F, DE JONGE S, HAMPEL H, BURGER K, STUBNER S, BOETSCH B, JURGEN MOLLER H, ACKENHEIL M, BONDY B, *Neurosci Lett*, 284 (2000) 113.
- 33. KENNEDY BP, ZIEGLER MG, HANSEN LA, THAL LJ, MASLIAH E, *J Neural Transm*, 110 (2003) 789.
- 34. DANIELCZYK W, STREIFLER M, KONRADI C, RIEDERER P, MOLL G, *Acta Psychiatr Scand*, 78 (1988) 730.
- 35. KIRK KM, WHITFIELD JB, PANG D, HEATH AC, MARTIN NG, *Am J Med Genet*, 105 (2001) 700.
- 36. IRVING JB, COURSWY RD, BUCHSBAUM MS, MURPHY DL, *Psychol Med*, 19 (1989) 79.
- 37. SCHALLING D, ASBERG M, EDMAN G, ORELAND L, *Acta Psychiatr Scand*, 76 (1987) 172.
- 38. EKBLÖM J, GARPENSTRAND H, DAMBERG M, CHEN K, SHIH JC, ORELAND L, *Neurosci Lett*, 258 (1998) 101.
- 39. BONGIOANNI P, F. GEMIGNANI, B. BOCCARDI, M. BORGNA B, ROSSI, *Ital J Neurol Sci*, 18 (1997) 151.
- 40. BURKE WJ, WEN LIS, CHUNG HD, RUGGIERO DA, KRISTAL BS, JOHNSON EM, LAMPE P, KUMAR VB, FRANKO M, WILLIAMS EA, ZAHM DS, *Neurotoxicol*, 25 (2004) 101.

D. Muck-Šeler

*Division of Molecular Medicine, Institute »Rudjer Bošković«, Bijenička 54, HR-10000 Zagreb, Croatia
e-mail: seler@irb.hr*

TROMBOCITNI SEROTONIN I MONOAMINOOKSIDAZA B U BOLESNIKA S AZHEIMEROVOM BOLESTI SA PSIHOTIČKIM SIMPTOMIMA

SAŽETAK

Post mortem istraživanja su pokazala promjene serotoninskog i kateholaminskog sustava u mozgu oboljelih od Alzheimerove bolesti (AB). Cilj istraživanja bio je odrediti koncentraciju trombocitnog serotonina (5-HT) i aktivnost trombocitne monoamino oksidaze tipa B (MAO-B) u bolesnika s AB sa ili bez psihotičnih simptoma i u skupini zdravih osoba. Dijagnoza vjerojatne AB (NINCDS-ADRDA kriterij) postavljena je u skladu s DSM-IV kriterijima. Za procjenu kognitivnog oštećenja korištena je Mini Mental Status Examination, a za određivanje psihotičnih simptoma Neuropsychiatric Inventory. U trombocitima 116 zdravih osoba (51 muškaraca, 65 žena), 70 bolesnika (10 muškaraca, 60 žena) sa psihotičkim simptomima i 151 bolesnika (32 muškarca, 119 žena) bez psihotičkih simptoma određena je koncentracija 5-HT i aktivnost MAO-B pomoću spektrofotometrijskih metoda. Koncentracija trombocitnog 5-HT bila je značajno snižena u bolesnika sa psihotičkim i nepsihotičkim simptomima te u nepsihotičkih bolesnika u odnosu na koncentraciju trombocitnog 5-HT u odgovarajućoj skupini zdravih žena i muškaraca. Aktivnost trombocitne MAO-B bila je povećana u muških i ženskih nepsihotičkih bolesnika s AB u usporedbi s aktivnošću u zdravoj kontroli odgovarajućeg spola. U trombocitima nepsihotičkih ženskih bolesnika pronađena je značajno povećana aktivnost MAO-B u odnosu na aktivnost enzima u trombocitima bolesnika sa psihotičkim simptomima. Rezultati istraživanja upućuju da bi aktivnost trombocitne MAO-B mogla biti biokemijski pokazatelj za razlikovanje psihotičkog i nepsihotičkog oblika AB.